Home > Journals > Panminerva Medica > Past Issues > Articles online first > Panminerva Medica 2020 May 14

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Panminerva Medica 2020 May 14

DOI: 10.23736/S0031-0808.20.03939-7

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

MicroRNA-1271-5p inhibits the tumorigenesis of ovarian cancer through targeting E2F5 and negatively regulates the mTOR signaling pathway

Qin LI, Junyu SHI, Xiaoli XU

Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Soochow University, The First People's Hospital of Changzhou, Changzhou, China


PDF


BACKGROUND: MicroRNA-1271-5p (miR-1271-5p) has been reported to participate in the progression of many human cancers. However, the role of miR-1271-5p still remains unclear in ovarian cancer (OC). Therefore, we explored the effect of miR-1271-5p on the development of OC in present study.
METHODS: We measured the miR-1271-5p expression via the qRT-PCR assay. Then the function of miR-1271-5p was analyzed through MTT and Transwell assays. The relationship among miR-1271-5p and E2F5 was verified by dual luciferase assay. The protein expression levels were examined through western blot.
RESULTS: MiR-1271-5p was downregulated in OC tissues which predicted poor prognosis of OC patients. Moreover, E2F5 was a direct target of miR-1271-5p in OC. And miR-1271-5p suppressed cell proliferation, migration and invasion in OC through targeting E2F5. Furthermore, E2F5 was upregulated in OC tissues which predicted poor prognosis of OC patients. Besides that, miR-1271-5p suppressed EMT and mTOR pathway in OC.
CONCLUSIONS: MiR-1271-5p inhibited the tumorigenesis of OC through targeting E2F5 and negatively regulated the mTOR signaling pathway.


KEY WORDS: miR-1271-5p; E2F5; Ovarian cancer; mTOR

top of page